Pliant Therapeutics
Jun 04, 2020
Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M;
Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children's Research Institute and the Benaroya Research Institute have got a promising finding that will turn off the destructive autoimmune response in Type 1 diabetes. This comprises editing the genes of patients' T cells. The team pre...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
